Results 1 to 10 of about 1,436,444 (347)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.

PLoS ONE, 2021
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely.
Christine Ambrose, Lihe Su, Lan Wu, Fay J Dufort, Thomas Sanford, Alyssa Birt, Benjamin J Hackel, Andreas Hombach, Hinrich Abken, Roy R Lobb, Paul D Rennert   +10 more
doaj   +3 more sources

CD19 CAR antigen engagement mechanisms and affinity tuning

Science Immunology, 2023
Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through an scFv (binder), the affinity of which is central to determining CAR T ...
Changhao He, J. Mansilla-Soto, N. Khanra, Mohamad Hamieh, Victor H. Bustos, Alice J. Paquette, Andreina Garcia Angus, Derek M. Shore, W. J. Rice, G. Khelashvili, M. Sadelain, J. Meyerson   +11 more
semanticscholar   +3 more sources

CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality

Scientific Reports, 2023
Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs carry tumor surface molecules such as tumor-associated antigens (TAAs) and/or checkpoint inhibitors,
V. M. Ukrainskaya, O. E. Musatova, D. V. Volkov, D. S. Osipova, D. S. Pershin, A. M. Moysenovich, E. G. Evtushenko, E. A. Kulakovskaya, E. G. Maksimov, H. Zhang, Y. P. Rubtsov, M. A. Maschan, A. V. Stepanov, A. G. Gabibov   +13 more
doaj   +2 more sources

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Journal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang, Caili Zhang, Yingchun Zhang, Yuting Fan, Jing Zhang, Xiaojin Lin, Ting Guo, Yangzuo Gu, Jieheng Wu, Jianmei Gao, Xing Zhao, Zhixu He   +11 more
doaj   +2 more sources

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Frontiers in Oncology, 2022
BackgroundThe CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor ...
Yuanyuan Liu, Yanxin Zheng, Tianyi Deng, Yue Huang, Ziwen Liu, Borui Zhan, Xusha Zhou, Runbin Yan, Jiangtao Ren, Yun Xing, Guixing Wu, Biao Zheng, Guang Hu, Wen Wang, Yonghong Liu, Jing Zhao, Xiaoqing Chen, Grace Guoying Zhou   +17 more
doaj   +2 more sources

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies

Nature Communications
Antigen escape relapse is a major challenge in targeted immunotherapies, including CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell for B-cell acute lymphoblastic leukemia (B-ALL).
Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton Merchant, Kaithlen Zen B. Pacheco, Sean A. Yamada-Hunter, Maria Caterina Rotiroti, Yuxuan Liu, Reema Baskar, Warren D. Reynolds, Brian J. Sworder, Bita Sahaf, Sean C. Bendall, Charles G. Mullighan, Ash A. Alizadeh, Allison B. Leahy, Regina M. Myers, Bonnie Yates, Hao-Wei Wang, Nirali N. Shah, Robbie G. Majzner, Crystal L. Mackall, Stephan A. Grupp, David M. Barrett, Elena Sotillo, Kara L. Davis   +25 more
doaj   +2 more sources

Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies

Journal of Immunology Research, 2021
Natural killer (NK) cells are part of the first line of defense that rapidly respond to malignant transformed cells. Chimeric antigen receptor- (CAR-) engineered NK cells, although are still at the preliminary stage, have been shown to be alternative to ...
Sudjit Luanpitpong, Jirarat Poohadsuan, Phatchanat Klaihmon, Surapol Issaragrisil   +3 more
doaj   +2 more sources

B cell CD19 is transferred between immune cells in mice and humans [PDF]

Nature Communications
When immune cells interact, they frequently exchange membrane-bound antigens. Our evolving understanding of these processes challenges the cellular specificity of lineage markers and therapeutic monoclonal antibodies. By using mouse and human B-T cell co-
Jasmin Ochs, Pia Schweineberg, Jacqueline Thode, Alica Blenkle, Leila Husseini, Matthias Klein, Tobias Bopp, Patrick Schindler, Friedemann Paul, Martin S. Weber   +9 more
doaj   +2 more sources

Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy

Molecular Therapy: Oncolytics, 2020
Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens.
Amin Aalipour, Fabrice Le Boeuf, Matthew Tang, Surya Murty, Federico Simonetta, Alexander X. Lozano, Travis M. Shaffer, John C. Bell, Sanjiv S. Gambhir   +8 more
doaj   +1 more source

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss

Cancer Cell International, 2021
Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li, Qing Zhang, Zhi Liu, Huijuan Shen, Yangmin Zhu, Zhao Zhou, Wen Ding, Siqi Han, Jie Zhou, Ruiming Ou, Min Luo, Shuang Liu   +11 more
doaj   +1 more source